Golden has been acquired by ComplyAdvantage.Read about it here ⟶

‌

US Patent 12018260 Tunable Reversir™ compounds

Patent 12018260 was granted and assigned to Alnylam Pharmaceuticals on June, 2024 by the United States Patent and Trademark Office.

Overview Structured Data Issues Contributors Activity

Is a

0

Patent attributes

Patent Applicant

Alnylam Pharmaceuticals

0

Current Assignee

Alnylam Pharmaceuticals

0

Patent Jurisdiction

United States Patent and Trademark Office

0

Patent Number

Patent Inventor Names

Ivan Zlatev0

Adam Castoreno0

Pushkal Garg0

Vasant Jadhav0

Jae Kim0

Martin Maier0

Date of Patent

June 25, 2024

0

Patent Application Number

175839310

Date Filed

January 25, 2022

0

Patent Citations

US Patent 9181549 Conjugated antisense compounds and their use

0

US Patent 7300922 Modulators of pharmacological agents

0

US Patent 8361980 Pharmaceutical compositions for treatment of microRNA related diseases

0

US Patent 8389488 Antidotes to antisense compounds

0

US Patent 9334497 Sequence-specific inhibition of small RNA function

0

Patent Primary Examiner

0

Patent abstract

The present invention relates, in general to agents that modulate the pharmacological activity of siRNAs. In addition, the invention relates generally to methods and systems for use in assessing the efficacy and safety of a pharmaceutical composition for use in the treatment or prophylaxis of a disease.

Timeline

No Timeline data yet.

Further Resources

Title

Author

Link

Type

Date

No Further Resources data yet.

References

Find more entities like US Patent 12018260 Tunable Reversir™ compounds

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.

Open Query Tool

Golden Query Tool